Suppr超能文献

巴西先天性肌弛缓综合征患者中常见的 CHRNE 突变。

A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome.

机构信息

Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Av. Enéas de Carvalho Aguiar, 255, 5o andar, sala 5084, Cerqueira César, São Paulo, 05403-900, Brazil.

Department of Neurosciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.

出版信息

J Neurol. 2018 Mar;265(3):708-713. doi: 10.1007/s00415-018-8736-8. Epub 2018 Jan 30.

Abstract

The most common causes of congenital myasthenic syndromes (CMS) are CHRNE mutations, and some pathogenic allelic variants in this gene are especially frequent in certain ethnic groups. In the southern region of Brazil, a study found the c.130dupG CHRNE mutation in up to 33% of families with CMS. Here, we aimed to verify the frequency of this mutation among individuals with CMS in a larger cohort of CMS patients from different areas of Brazil and to characterize clinical features of these patients. Eighty-four patients with CMS, from 72 families, were clinically evaluated and submitted to direct sequencing of the exon 2 of CHRNE. The c.130dupG mutation was found in 32 patients (23 families), with 26 patients (19 families, 26.3%) in homozygosis, confirming its high prevalence in different regions of Brazil. Among the homozygous patients, the following characteristics were frequent: onset of symptoms before 2 years of age (92.3%), little functional restriction (92.3%), fluctuating symptoms (100%), ocular muscle impairment (96.1%), ptosis (100%), limb weakness (88.4%), response to pyridostigmine (100%), facial involvement (77%), and bulbar symptoms (70.8%). The pretest probability of finding at least one allele harbouring the c.130dupG mutation was 38.1%. Selecting only patients with impaired eye movement together with limb weakness and improvement with pyridostigmine, the probability increases to 72.2%. This clinical pre-selection of patients is likely a useful tool for regions where CHRNE mutations have a founder effect. In conclusion, the CHRNE mutation c.130dupG leads to fairly benign natural course of the disease with relative homogeneity.

摘要

最常见的先天性肌无力综合征(CMS)的病因是 CHRNE 突变,该基因的一些致病变异体在某些种族中尤为常见。在巴西南部地区,一项研究发现,CMS 患者的家系中高达 33%存在 CHRNE 基因 c.130dupG 突变。在此,我们旨在验证巴西不同地区更大 CMS 患者队列中该突变的频率,并对这些患者的临床特征进行分析。对 72 个 CMS 患者家系的 84 名 CMS 患者进行了临床评估,并对 CHRNE 外显子 2 进行了直接测序。在 32 名患者(23 个家系)中发现了 c.130dupG 突变,其中 26 名患者(19 个家系,26.3%)为纯合子,证实了其在巴西不同地区的高发生率。在纯合子患者中,以下特征很常见:症状在 2 岁前出现(92.3%),功能受限小(92.3%),症状波动(100%),眼肌受累(96.1%),上睑下垂(100%),肢体无力(88.4%),对吡啶斯的明有反应(100%),面肌无力(77%)和球部症状(70.8%)。发现至少一个携带 c.130dupG 突变等位基因的先验概率为 38.1%。选择仅存在眼运动障碍、肢体无力和吡啶斯的明改善的患者,概率增加至 72.2%。对于 CHRNE 突变具有奠基者效应的地区,这种患者的临床预筛选可能是一种有用的工具。总之,CHRNE 突变 c.130dupG 导致疾病具有相对均一的良性自然病程。

相似文献

1
A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome.
J Neurol. 2018 Mar;265(3):708-713. doi: 10.1007/s00415-018-8736-8. Epub 2018 Jan 30.
5
CHRNE compound heterozygous mutations in congenital myasthenic syndrome: A case report.
Medicine (Baltimore). 2018 Apr;97(17):e0347. doi: 10.1097/MD.0000000000010347.
7
Congenital myasthenic syndrome in Turkey: clinical and genetic features in the long-term follow-up of patients.
Acta Neurol Belg. 2021 Apr;121(2):529-534. doi: 10.1007/s13760-019-01246-9. Epub 2019 Nov 26.
8
A CHRNE frameshift mutation causes congenital myasthenic syndrome in young Jack Russell Terriers.
Neuromuscul Disord. 2015 Dec;25(12):921-7. doi: 10.1016/j.nmd.2015.09.005. Epub 2015 Sep 8.
9
Congenital myasthenic syndrome due to homozygous CHRNE mutations: report of patients in Arabia.
J Neuroophthalmol. 2011 Mar;31(1):42-7. doi: 10.1097/WNO.0b013e3181f50bea.
10
A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin.
Neurology. 1999 Oct 22;53(7):1564-9. doi: 10.1212/wnl.53.7.1564.

引用本文的文献

1
The Importance of Early Treatment of Inherited Neuromuscular Conditions.
J Neuromuscul Dis. 2024;11(2):253-274. doi: 10.3233/JND-230189.
2
Electrophysiological evaluation of the neuromuscular junction: a brief review.
Arq Neuropsiquiatr. 2023 Dec;81(12):1040-1052. doi: 10.1055/s-0043-1777749. Epub 2023 Dec 29.
3
Genetic, serological and clinical evaluation of childhood myasthenia syndromes- single center subgroup analysis experience in Turkey.
Acta Neurol Belg. 2023 Dec;123(6):2325-2335. doi: 10.1007/s13760-023-02370-3. Epub 2023 Sep 1.
4
Leveraging pleiotropy to discover and interpret GWAS results for sleep-associated traits.
PLoS Genet. 2022 Dec 27;18(12):e1010557. doi: 10.1371/journal.pgen.1010557. eCollection 2022 Dec.
5
Genetic and clinical evaluation of congenital myasthenic syndromes with long-term follow-up: experience of a tertiary center in Turkey.
Acta Neurol Belg. 2023 Oct;123(5):1841-1847. doi: 10.1007/s13760-022-02090-0. Epub 2022 Sep 12.
6
Myasthenia gravis in clinical practice.
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):257-265. doi: 10.1590/0004-282X-ANP-2022-S105.
7
Congenital myasthenic syndrome in a cohort of patients with 'double' seronegative myasthenia gravis.
Arq Neuropsiquiatr. 2022 Jan;80(1):69-74. doi: 10.1590/0004-282X-ANP-2020-0575.
8
Fluctuating weakness: clue in the eyes!
BMJ Case Rep. 2020 Dec 28;13(12):e239211. doi: 10.1136/bcr-2020-239211.
9
Pharmacological Strategy for Congenital Myasthenic Syndrome with CHRNE Mutations: A Meta-Analysis of Case Reports.
Curr Neuropharmacol. 2021;19(5):718-729. doi: 10.2174/1570159X18666200729092332.
10
Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome.
Emerg Top Life Sci. 2019 Mar;3(1):19-37. doi: 10.1042/ETLS20180100. Epub 2019 Jan 28.

本文引用的文献

1
Molecular characterization of congenital myasthenic syndromes in Spain.
Neuromuscul Disord. 2017 Dec;27(12):1087-1098. doi: 10.1016/j.nmd.2017.08.003. Epub 2017 Aug 18.
2
The Increasing Genetic and Phenotypical Diversity of Congenital Myasthenic Syndromes.
Neuropediatrics. 2017 Aug;48(4):294-308. doi: 10.1055/s-0037-1602832. Epub 2017 May 15.
3
Congenital myasthenic syndrome in Israel: Genetic and clinical characterization.
Neuromuscul Disord. 2017 Feb;27(2):136-140. doi: 10.1016/j.nmd.2016.11.014. Epub 2016 Nov 24.
4
Nonlethal CHRNA1-Related Congenital Myasthenic Syndrome with a Homozygous Null Mutation.
Can J Neurol Sci. 2017 Jan;44(1):125-127. doi: 10.1017/cjn.2016.322. Epub 2016 Oct 17.
6
Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.
Neurology. 2015 Sep 22;85(12):1043-7. doi: 10.1212/WNL.0000000000001952.
7
Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.
Lancet Neurol. 2015 May;14(5):461. doi: 10.1016/S1474-4422(15)00010-1. Epub 2015 Mar 26.
8
Congenital myasthenic syndromes: an update.
Pract Neurol. 2013 Apr;13(2):80-91. doi: 10.1136/practneurol-2012-000404.
10
Molecular characterisation of congenital myasthenic syndromes in Southern Brazil.
J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):973-7. doi: 10.1136/jnnp.2009.177816. Epub 2010 Jun 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验